Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03308942
Title Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Tesaro, Inc.
Indications

lung non-small cell carcinoma

Therapies

Niraparib

Niraparib + Pembrolizumab

Dostarlimab-gxly + Niraparib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
GSK Investigational Site Whittier California 90603 United States Details
GSK Investigational Site Port Saint Lucie Florida 34952 United States Details
GSK Investigational Site Atlanta Georgia 30322 United States Details
GSK Investigational Site Harvey Illinois 60426 United States Details
GSK Investigational Site Tinley Park Illinois 60487 United States Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site Morristown New Jersey 07962-1956 United States Details
GSK Investigational Site Buffalo New York 14263 United States Details
GSK Investigational Site Durham North Carolina 27710 United States Details
GSK Investigational Site Canton Ohio 44718 United States Details
GSK Investigational Site Cleveland Ohio 44106 United States Details
GSK Investigational Site Columbus Ohio 31904 United States Details
GSK Investigational Site Toledo Ohio 43623 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Kennewick Washington 99336 United States Details
GSK Investigational Site Tacoma Washington 98405 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field